Barrett Katz - Jan 13, 2023 Form 4 Insider Report for Viridian Therapeutics, Inc.\DE (VRDN)

Role
Chief Medical Officer
Signature
/s/ Lara Meisner, Attorney-in-Fact for Barrett Katz
Stock symbol
VRDN
Transactions as of
Jan 13, 2023
Transactions value $
-$410,391
Form type
4
Date filed
1/18/2023, 04:58 PM
Previous filing
Jan 11, 2023
Next filing
Feb 10, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRDN Common Stock Options Exercise $95.5K +4.15K $23.03 4.15K Jan 13, 2023 Direct
transaction VRDN Common Stock Sale -$153K -4.15K -100% $37.01 0 Jan 13, 2023 Direct F1
transaction VRDN Common Stock Options Exercise $572K +24.9K $23.03 24.9K Jan 17, 2023 Direct
transaction VRDN Common Stock Sale -$925K -24.9K -100% $37.21 0 Jan 17, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRDN Stock Option (Right to Buy) Options Exercise $0 -4.15K -1.4% $0.00 292K Jan 13, 2023 Common Stock 4.15K $23.03 Direct F3
transaction VRDN Stock Option (Right to Buy) Options Exercise $0 -24.9K -8.52% $0.00 267K Jan 17, 2023 Common Stock 24.9K $23.03 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $37.00 to $37.05. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F2 This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $37.00 to $37.58. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 The option vested 25% on January 18, 2022 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date.